MORPHOSYS - Key Persons
Job Titles:
- Business Development Executive
- Chief Business Officer
- Member of the Executive Committee
Barbara Krebs-Pohl is a highly regarded business development executive with an outstanding track record of accomplishment of revenues and forging successful alliances with pharma and biotechnology companies worldwide.
Since joining MorphoSys in 1998, Barbara has successfully led R&D teams, international alliances and negotiation teams spanning a broad variety of deal structures. She has been instrumental in program search & evaluation, portfolio strategy and a multitude of transactions, including the in-licensing of tafasitamab from Xencor, the long-term HuCAL alliance with Novartis and the co-development and co-commercialization partnership with Incyte. She is also the winner of the "Astra Zeneca Business Development Executive of the Year 2013" Award.
Prior to joining MorphoSys, Barbara earned the opportunity to work with Nobel Prize winner Sir Greg Winter at MRC/LMB Cambridge, UK. She holds a Ph.D. from the University of Mainz in Immunology, theoretical Physics and Biochemistry. She is a Master of Science (MSc) Chemistry from the University of Cologne and further trained at the RWTH Aachen University with focus on Medical Biology and Bacteriology.
Job Titles:
- General Counsel
- Member of the Executive Committee
- Chief Legal and Human Resources Officer
Charlotte Lohmann joined MorphoSys in May 2012 as General Counsel. She is a very experienced lawyer with 25 years of professional practice, having worked in both top tier international audit and law firms as well as in publicly listed biotech companies. In March 2023 she was appointed Chief Legal Officer and in December 2023 she was appointed Chief Legal and Human Resources Officer. In her current role she is leading the Legal, Compliance, Intellectual Property and Human Resources Departments.
She is an accomplished executive that has established solution-oriented departments with a focus on performance, effectiveness and making the departments a true business partner. She has been successful in setting up and executing international projects as well as public listings on Frankfurt Stock Exchange and Nasdaq and has vast experience in advising management and supervisory boards (both as General Counsel/Chief Legal Officer and supervisory board member).
Prior to joining MorphoSys she worked for Wilex AG as Sr. VP Legal Affairs & Human Resources and for KPMG as Corporate Lawyer. Charlotte Lohmann holds a Law Degree from the University of Munich and is an accredited lawyer in Germany.
Job Titles:
- Chief Executive Officer
- Member of the Executive Committee
- Member of the for the SUPERVISORY BOARD
As CEO, Jean-Paul Kress leads MorphoSys in its mission - More life for people with cancer - by focusing on translating scientific innovation into medicines that can redefine how cancer is treated.
Since becoming CEO in 2019, Jean-Paul has led a strategic and cultural transformation to build a focused global biopharmaceutical company. As part of this evolution, Jean-Paul championed the company's acquisition of Constellation Pharmaceuticals in 2021. This landmark achievement for the company enriched MorphoSys' pipeline with promising investigational medicines - most importantly a potential breakthrough therapy to treat myelofibrosis. Today, MorphoSys is pursuing multiple opportunities to deliver safer and more effective medicines for people living with blood cancers and solid tumors.
Prior to joining MorphoSys, Jean-Paul was the CEO of Syntimmune, where he sharpened the company's focus on late-stage clinical development, resulting in its acquisition by Alexion. He has held several senior leadership roles at other pharmaceutical companies, including Biogen, Sanofi, Gilead and AbbVie.
Jean-Paul also served as Chair of the Board of Directors at ERYTECH Pharma, where he ushered in the company's merger with Pherecydes. Prior to that, he was a member of Sarepta Therapeutics' Board of Directors.
Jean-Paul received his M.D. from Faculté Necker-Enfants Malades in Paris and graduate and post-graduate degrees in biochemistry and in molecular and cellular pharmacology from Ecole Normale Supérieure in Paris.
Job Titles:
- Chairman
- CHAIRMAN of the SUPERVISORY BOARD
- Member of the for the SUPERVISORY BOARD
Job Titles:
- Executive
- General Manager
- Member of the Executive Committee
Joe Horvat is a global executive with more than 25 years of successful leadership, early development and commercialization experience in both small biotech and large pharmaceutical organizations. He joined MorphoSys, U.S. Inc. as General Manager in May 2021.
Previously, Joe was CEO of Oncopeptides Inc. (North America subsidiary of Oncopeptides AB) where he built a North America infrastructure and assembled a high performing team that accelerated plans to be launch ready in less than a year. Joe also spent over nine years at EMD Serono (U.S. Subsidiary of Merck KGaA of Darmstadt Germany) in various roles of increasing responsibility including leading the launch of the organization's first global product (Bavencio®) and building EMD Serono's first oncology commercial footprint. He also spent over a decade of his early career at Bristol-Myers Squibb in global, U.S. and international marketing roles across various therapeutic areas, including cardiovascular, neuroscience and oncology. Joe has developed a solid track record that spans infrastructure building, general management, business development support, commercialization across all stages, marketing, and sales.
Joe holds a Bachelor of Science in Specialization in Neuropsychology from the University of Alberta.
Job Titles:
- Chief Financial Officer
- Member of the Executive Committee
Lucinda Crabtree, Ph.D., joined MorphoSys as Chief Financial Officer in August 2023. She has broad biotech experience from various corporate roles and her time as an investment professional and board observer.
Prior to joining MorphoSys, Lucinda served as the Chief Financial Officer at Autolus Therapeutics, a clinical-stage biopharmaceutical company developing T cell therapies. In her previous roles at Autolus, she led Finance, Business Strategy and Planning, as well as Investor Relations and Corporate Communications functions. Prior to her time at Autolus, Lucinda worked for several years as a senior investment professional on both the buy and the sell sides, and she served as a board observer for several private healthcare companies. Firms she has worked at include Woodford Investment Management, Panmure Gordon, Goldman Sachs, J.P. Morgan and Jefferies.
Lucinda started her career as a research scientist at a U.K.-based biotech company. She holds a first class Bachelor of Science degree in Physiology and Pharmacology from University College London and a Ph.D. in Pharmacology from University College London.
Job Titles:
- Leader
- Member of the Executive Committee
- SVP, Global Head of Technical Operations
Luisa Ciccarelli is a leader in the biopharmaceutical industry with over 15 years of experience working for research organizations and international pharmaceutical companies.
Luisa joined MorphoSys in August 2021 as Head of Global Quality from Novartis Austria, where she was Head of Production for one of the company's most prominent manufacturing sites. Prior to that, she held different leadership positions in quality, process development and validation and product manufacturing at different Novartis sites, including in Italy, Singapore and the U.S. In these roles she gained extensive international exposure and experience in manufacturing, quality and regulatory compliance for small and large molecules products, building a culture that recognized and understood the value and importance of quality.
Luisa holds a master's degree in Chemistry and Pharmaceutical Technologies from the University Federico II of Naples, Italy and is an accredited pharmacist.
Sharon Curran serves as the ESG expert on the Supervisory Board of MorphoSys.
Job Titles:
- Member of the Management Board
The member of the Management Board Sung Lee has resigned from his position as member of the Management Board with effect as of the end of March 17, 2023. Instead, Charlotte Lohmann has been appointed as member of the Management Board with effect as of March 1, 2023 until the end of August 31, 2023. Against this background, the Supervisory Board has updated the proportion of women on the Management Board and set it at 50%. This target value shall apply until June 30, 2025. With effect as of August 8, 2023 Lucinda Crabtree, Ph.D., has further been appointed as member of the Management Board. The defined target value for the proportion of women on the Management Board is therefore met.
Job Titles:
- Head of Corporate Affairs
- Member of the Executive Committee
- Senior Vice President
Thomas is Senior Vice President and Head of Corporate Affairs at MorphoSys. An established cross-functional corporate affairs executive, he has held various leadership roles across multiple disciplines during his 20-plus years in the biopharmaceutical industry.
In his role, Thomas leads engagement with MorphoSys' key stakeholders overseeing communications, investor relations, corporate responsibility and patient advocacy. Before joining MorphoSys in 2020 as the company's Head of Corporate Communications, he held several senior positions at Pfizer. During his time at Pfizer, Thomas led communications for the company's global Oncology group, which encompassed a growing $12 billion portfolio of medicines. Prior to that, he also oversaw the company's communications team in Germany.
Thomas holds a Bachelor of Arts in Business Administration from the University of Cooperative Education in Mannheim and a Master of Arts in Media and Communication Studies from the Freie Universität in Berlin.
Job Titles:
- Member of the Executive Committee
- Chief Research and Development Officer
Tim Demuth is a seasoned biopharma executive with broad leadership experience in drug development, with a focus in oncology.
He joined MorphoSys from Pieris Pharmaceuticals, Inc, where he was Chief Medical Officer. Prior to this position, he was Vice President and Head of Global Clinical Development Oncology at Merck KGaA, where he was responsible for the early- and late-stage oncology pipeline of small molecules, antibodies and antibody-drug conjugates, as well as for the end-to-end development strategy for oncology. Previously, he led the Clinical Development Unit of Hematology Biopharma Development at Sandoz AG, a division of Novartis AG. Tim held other leadership roles at Novartis AG, Italfarmaco S.p.A and Merck & Co. He received M.D. and Ph.D. degrees from Johannes-Gutenberg-University, Mainz, Germany and was trained in Mainz and at Ludwig-Maximilian-University, Munich, Germany. He has also served as a Post-Doctoral Fellow at the Translational Genomics Research Institute in Phoenix, Arizona.